The absolute rates are low for both medications
Consult your doctor if you experience any of the following: Do not use semaglutide if you have a family history of thyroid cancer, or if you have a condition called multiple endocrine neoplasia syndrome (MEN 2) which causes tumours on the endocrine glands
When compared to individuals taking DPP4 inhibitors, the GLP-1 group showed a recurrence risk of 14.4%, while the DPP4 inhibitor group had a risk of 23.3%
If you experience significant side effects, consult your healthcare provider for guidance
Anyone searching Google would find pages of med spas and telehealth companies with weight loss programs that include semaglutide
Cagrilintide vs semaglutide (Wegovy/Ozempic) Mechanism: Cagrilintide: Amylin receptor agonist Semaglutide: GLP-1 receptor agonist Different pathways Weight loss: Cagrilintide alone: 10-12% Semaglutide alone: 10-15% Similar efficacy monotherapy Gastric emptying: Cagrilintide: Very strong delay Semaglutide: Moderate delay Cagrilintide more powerful Side effects: Cagrilintide: More GI effects (stronger gastric slowing) Semaglutide: Moderate GI effects Cagrilintide harder to tolerate for some Availability: Cagrilintide: Investigational (not approved) Semaglutide: FDA approved, widely available Semaglutide easier to obtain currently Combination potential: Synergistic together (CagriSema) 15-25% weight loss combined Best of both mechanisms Verdict: Similar monotherapy efficacy, but combine for maximum results